Answers are grounded in this paper and cite their sources.
For settings where there is limited or no critical care delivery, implementation of EECC could be a highly cost-effective investment. It could reduce mortality and morbidity for critically ill COVID-19 patients, and its cost effectiveness falls within the range considered 'highly cost effective'. Further research is needed to explore the potential of EECC to generate even greater benefits and value for money when patients with diagnoses other than COVID-19 are accounted for.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: